Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of its enticing dividend yield, a bit risky.
In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss how AbbVie is trying to protect itself from Humira competition in the future and if its efforts are enough to warrant buying its shares.
A full transcript follows the video.
Source: Fool.com
Gilead Sciences Inc Stock
€71.28
0.480%
We see a rather positive sentiment for Gilead Sciences Inc with 11 Buy predictions and 1 Sell predictions.
With a target price of 85 € there is a slightly positive potential of 19.25% for Gilead Sciences Inc compared to the current price of 71.28 €.
